4,877 reports of this reaction
8.4% of all RABEPRAZOLE SODIUM reports
#1 most reported adverse reaction
CHRONIC KIDNEY DISEASE is the #1 most commonly reported adverse reaction for RABEPRAZOLE SODIUM, manufactured by Waylis Therapeutics LLC. There are 4,877 FDA adverse event reports linking RABEPRAZOLE SODIUM to CHRONIC KIDNEY DISEASE. This represents approximately 8.4% of all 58,263 adverse event reports for this drug.
Patients taking RABEPRAZOLE SODIUM who experience chronic kidney disease should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CHRONIC KIDNEY DISEASE is moderately reported among RABEPRAZOLE SODIUM users, representing a notable but not dominant share of adverse events.
In addition to chronic kidney disease, the following adverse reactions have been reported for RABEPRAZOLE SODIUM:
The following drugs have also been linked to chronic kidney disease in FDA adverse event reports:
CHRONIC KIDNEY DISEASE has been reported as an adverse event in 4,877 FDA reports for RABEPRAZOLE SODIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
CHRONIC KIDNEY DISEASE accounts for approximately 8.4% of all adverse event reports for RABEPRAZOLE SODIUM, making it one of the most commonly reported side effect.
If you experience chronic kidney disease while taking RABEPRAZOLE SODIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.